Sign In
Buy AKRO
$54.65
+0 (+0%)
At Close: Mar 06, 2026
NEW ORLEANS , May 3, 2024 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 25, 2024 to file lead plaintiff applications in a securities
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Akero Therape
Akero Therapeutics, Inc. (AKRO) Investor Notice: Robbins LLP Reminds Stockholders of the Akero Therapeutics, Inc. Class Action
09:29pm, Thursday, 02'nd May 2024
SAN DIEGO--(BUSINESS WIRE)---- $AKRO #AKRO--Robbins LLP Investigates Allegations that Akero Therapeutics, Inc. (AKRO) Misled Investors Regarding Viability and Efficacy of its Drug Candidate.
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Akero Therapeutics, Inc. (AKRO) on Behalf of Investors
05:31pm, Thursday, 02'nd May 2024
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Akero Therapeutics, Inc. (“Akero” or the “Company”) (NASDAQ: AKRO) investors concerning t
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc.with Losses to Contact the Firm
04:00pm, Thursday, 02'nd May 2024
LOS ANGELES, CA / ACCESSWIRE / May 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Akero Therapeutics, Inc. ("Akero" o
The Law Offices of Frank R. Cruz Announces Investigation of Akero Therapeutics, Inc. (AKRO) on Behalf of Investors
02:47pm, Thursday, 02'nd May 2024
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Akero Therapeutics, Inc. (“Akero” or the “Company”) (NASDAQ: AKRO) on behalf of investors concernin
Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study
03:16pm, Tuesday, 05'th Mar 2024
Akero (AKRO) reports positive results from its mid-stage study of efruxifermin in pre-cirrhotic metabolic dysfunction-associated steatohepatitis patients at week 96. The stock gains 12%.
Akero: Phase 2b NASH Data Bodes Well For Phase 3 SYNCHRONY Program
02:49pm, Monday, 04'th Mar 2024
Akero Therapeutics, Inc. preliminary positive 96-week results from the phase 2b HARMONY study achieved, which used EFX for the treatment of pre-cirrhotic MASH patients with F2-F3 Fibrosis. The global
Akero's lead drug helps improve scarring in fatty liver disease patients
06:11am, Monday, 04'th Mar 2024
Akero Therapeutics said on Monday its lead experimental drug to treat a type of fatty liver disease helped improve scarring in patients' organ after 96 weeks, meeting the main goal of a mid-stage stud
Wall Street Analysts Predict a 58.87% Upside in Akero Therapeutics, Inc. (AKRO): Here's What You Should Know
10:56am, Friday, 01'st Mar 2024
The mean of analysts' price targets for Akero Therapeutics, Inc. (AKRO) points to a 58.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreeme
Investor webcast on Monday, March 4 at 8:00 a.m. ET to present clinical data Investor webcast on Monday, March 4 at 8:00 a.m. ET to present clinical data
Here's Why Akero Therapeutics, Inc. (AKRO) Is a Great 'Buy the Bottom' Stock Now
10:56am, Monday, 05'th Feb 2024
Akero Therapeutics, Inc. (AKRO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agree
Is Akero Therapeutics (AKRO) Stock Outpacing Its Medical Peers This Year?
10:41am, Tuesday, 30'th Jan 2024
Here is how Akero Therapeutics, Inc. (AKRO) and Perspective Therapeutics (CATX) have performed compared to their sector so far this year.
Biotech Stock Rally Could Soon Take a Breather
03:55pm, Tuesday, 09'th Jan 2024
The shares of Akero Therapeutics Inc (NASDAQ:AKRO) have been steadily climbing from their November lows following a steep early October bear gap , though pressure seems to have appeared at the $25 lev
Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
08:15am, Wednesday, 03'rd Jan 2024
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious meta
